Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Share-based Compensation (2016 - 2025)

Lipocine (LPCN) has disclosed Share-based Compensation for 13 consecutive years, with $53256.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation fell 50.64% year-over-year to $53256.0, compared with a TTM value of $289463.0 through Sep 2025, down 37.43%, and an annual FY2024 reading of $409000.0, down 37.5% over the prior year.
  • Share-based Compensation was $53256.0 for Q3 2025 at Lipocine, down from $65205.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $178000.0 in Q1 2023 and bottomed at $53256.0 in Q3 2025.
  • Average Share-based Compensation over 5 years is $131211.5, with a median of $147566.0 recorded in 2021.
  • The sharpest move saw Share-based Compensation tumbled 68.51% in 2021, then rose 18.22% in 2023.
  • Year by year, Share-based Compensation stood at $154946.0 in 2021, then increased by 6.6% to $165176.0 in 2022, then decreased by 7.11% to $153438.0 in 2023, then tumbled by 34.83% to $100000.0 in 2024, then crashed by 46.74% to $53256.0 in 2025.
  • Business Quant data shows Share-based Compensation for LPCN at $53256.0 in Q3 2025, $65205.0 in Q2 2025, and $71002.0 in Q1 2025.